Home / Medications / Zepbound

Medication guide

Zepbound (tirzepatide)

Zepbound is Eli Lilly's brand of tirzepatide for chronic weight management and obstructive sleep apnea in adults with obesity. It is a weekly injection, sold as single-dose vials and as a KwikPen.

Updated October 2026

Advertiser disclosure: We may earn a commission from links on this page, at no cost to you. Affiliate disclosure.

Not medical advice: This is general information. Talk to your doctor before starting, stopping or changing any medication. Medical disclaimer.

Key facts

ItemDetails
Active ingredientTirzepatide (GIP and GLP-1 receptor agonist)
MakerEli Lilly
FormsWeekly injection: single-dose vials and KwikPen; doses 2.5–15 mg
FDA-approved usesChronic weight management in adults with obesity, or overweight with a weight-related condition; moderate to severe obstructive sleep apnea in adults with obesity
Self-pay price (LillyDirect)Vials $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) per month; KwikPen about $299–$449 by dose

FDA approval timeline

DateMilestone
November 2023Approved for chronic weight management
December 2024Approved for obstructive sleep apnea in adults with obesity
February 2026KwikPen available to self-pay patients via LillyDirect
July 2026Zepbound KwikPen included in the Medicare GLP-1 Bridge

What the trials found

In SURMOUNT-1, adults on the highest dose lost about 21% of body weight on average over 72 weeks. In the head-to-head SURMOUNT-5 trial, tirzepatide produced about 20% average weight loss compared with about 14% for semaglutide. These are trial averages, not a promise of individual results.

Side effects and warnings

The most common side effects in trials were nausea, diarrhea, vomiting and constipation, mostly while the dose was increasing. The label carries a boxed warning about thyroid C-cell tumors seen in rodents. See our side effects guide.

Where to get Zepbound

Zepbound needs a prescription. Telehealth programs we review that list it:

ProviderTypical priceOur score
Ro Body ProgramFrom ~$448/mo all-in (Wegovy pill)Our score: 9.3/10
LillyDirectZepbound vials ~$299–$449/mo; Foundayo from $149/moOur score: 9.1/10
FoundFrom ~$289/moOur score: 8.6/10
BiltRxCompounded semaglutide from $81/mo; tirzepatide from $129/mo (+ consult and shipping)Our score: 8.4/10
WeightWatchers Clinic~$373/mo after intro monthOur score: 8.2/10

Compare prices in our tracker → · Estimate your monthly cost →

Compounded GLP-1s are not FDA-approved. They are not equivalent to Zepbound. Which medication, if any, is suitable is decided by a licensed clinician.

FAQ

What is Zepbound?

Zepbound is a brand-name prescription medicine made by Eli Lilly. Its active ingredient is tirzepatide.

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide is not FDA-approved and is not equivalent to Zepbound. The FDA does not review compounded drugs for safety, effectiveness or quality.

How do I get Zepbound?

Zepbound requires a prescription from a licensed clinician, who decides whether it is suitable for you. Prescriptions can be filled at retail pharmacies, through telehealth programs or at the manufacturer's self-pay pharmacy.

Related guides

  • Zepbound vials vs pens: How the two Zepbound formats differ in price, how you inject them and whether insurance applies.
  • Semaglutide vs tirzepatide: How Wegovy and Zepbound differ in how they work, results, side effects and price.
  • LillyDirect vs NovoCare: How Eli Lilly's and Novo Nordisk's self-pay pharmacies work, what they charge by dose and what you need to order.
  • Stopping a GLP-1: What trials found about weight and health markers after people stopped semaglutide or tirzepatide.

Sources

GLP1Rated is for general information only and is not medical advice. GLP-1 medications are prescription drugs with real risks and side effects. Talk to a licensed clinician before starting, stopping or changing any medication or supplement.

The GLP-1 brief

Price drops, new approvals and provider changes, once a week. No spam, unsubscribe any time.